Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

iShares Biotechnology ETF (NQ:IBB)

155.95 -3.43 (-2.15%)
Streaming Delayed Price Updated: 11:48 AM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about iShares Biotechnology ETF

< Previous 1 2 3 4 5 6 7 8 9
...
26 27 Next >
Biotech ETFs Come Alive As Illumina Soars 23% — Is The Genomics Winter Finally Over?
Illumina's 23% post-earnings rally revives optimism across biotech ETFs as investors bet on a genomics rebound and ex-China growth in 2025. 
Via Benzinga
Topics ETFs
Intellia Freezes Key Trial After Serious Liver Event, Stock Tumbles
Intellia Therapeutics (NASDAQ: NTLA) paused their Phase 3 MAGNITUDE and MAGNITUDE-2 trials after a serious liver-related adverse event. 
Via Benzinga
SciSparc Expands Biotech Ambitions, Buys Stake In Miza III Ventures
SciSparc traded higher after the company announced it had signed a definitive agreement to acquire a controlling stake in Miza III Ventures. 
Via Benzinga
Enpro Moves To Boost Profits With $280 Million Acquisition Push
Enpro Inc. (NYSE: NPO) acquiring AlpHa Measurement Solutions and Overlook Industries for $280 million in cash. 
Via Benzinga
White House Clarifies Recent Pharmaceutical Tariffs Exempt Countries with Trade Agreements: Report
Via Stocktwits
CDC Turmoil Escalates: Kennedy To Testify In Senate After Director Fired, Senior Officials Quit
Via Stocktwits
CDC Chief Susan Monarez Pushed Out After Weeks On Job As RFK Jr. Overhauls Agency — She’s Fighting Back
Via Stocktwits
Financial Markets Signal Near 100% Probability of Fed Rate Cut: What it Means for the Economy and Investors
The financial markets are currently flashing a near 100% probability of a Federal Reserve interest rate cut at the upcoming October 28-29 Federal Open Market Committee (FOMC) meeting. This overwhelming... 
Via MarketMinute
Topics Bonds Credit Cards Economy
Destiny Wealth Sells $8.1 Million in IBB Shares — Here’s Why Biotech Stocks Are Lagging
Via The Motley Fool
Topics Artificial Intelligence ETFs Regulatory Compliance
How Trump's Shutdown Standoff Could Hand Health-Care ETFs A Lifeline
Trump's comments on health-care negotiations with Democrats can put ETFs like XLV, IHF, and XHS back on investors' radar as Washington's shutdown drags on. 
Via Benzinga
Topics ETFs Government
SciSparc And AutoMax Call Off Merger
SciSparc ends merger with AutoMax, sets loan repayment terms, and refocuses on CNS drug development and innovation. 
Via Benzinga
Dallas Fed President Lorie Logan Warns Against Premature Rate Cuts, Prioritizing Inflation Fight
Federal Reserve Bank of Dallas President Lorie Logan delivered a stark warning on October 2nd and reiterated it today, October 3rd, 2025, emphasizing the paramount importance of tackling persistent... 
Via MarketMinute
Topics Bonds Credit Cards Economy
Pharma Tariffs Back In Spotlight On New Trump Threat
President Donald Trump threatened 100% tariffs on some drug imports. 
Via Investor's Business Daily
Topics ETFs Government World Trade
Small Cap Revival: Could Rate Cuts Spark a Rebound in Smaller Companies?
As whispers of impending interest rate cuts grow louder from central banks worldwide, a new wave of optimism is beginning to ripple through the often-overlooked small-cap sector. These nimble,... 
Via MarketMinute
Topics Economy
Biotech Sector May Flip to Market Leader by Year-End
As rate cuts loom and after years of lagging, the biotech sector is showing signs of life, with IBB outpacing the benchmark S&P 500 on the quarter. 
Via MarketBeat
Topics ETFs Economy Stocks
Trump's Biotech Playbook Ignites $350 Billion Investment Blitz
Trump's policies have sparked a $350B investment surge in US biotech, creating job & revenue opportunities. Investors can track with XBI or IBB ETFs and consider JNJ, NVS, LLY, AZN, BMY as potential... 
Via Benzinga
Topics ETFs Government
FDA Is Reportedly ‘Taking A Hard Look’ To Evaluate Whether Sarepta’s Gene Therapy Elevidys Should Remain On The Market
The FDA had already been investigating two earlier deaths linked to Elevidys. 
Via Stocktwits
Topics Death
Donald Trump Is Finally Making Good On Pharma Tariffs Threats, But Stocks Yawn
President Donald Trump said late Tuesday his administration will begin implementing pharmaceutical tariffs next month. 
Via Investor's Business Daily
Topics ETFs Government World Trade
Trump Threatens To Slam Pharmaceuticals With Up To 200% Tariffs
President Donald Trump threatened Tuesday to levy up to 200% tariffs on drugs imported into the U.S. "very soon." 
Via Investor's Business Daily
Topics ETFs Economy Government
US Supreme Court Reportedly Upholds Part Of Obamacare That Guarantees Health Insurers Cover Preventive Care
The Obamacare law requires health insurers to provide preventive care, including cancer screenings and HIV prevention medication, at no cost to patients. 
Via Stocktwits
Topics Government Lawsuit Religion
Novavax Scores Key FDA Win, Shares Jump 19% As Sanofi Unlocks Milestone Payment
Novavax's COVID-19 vaccine, Nuvaxovid™, receives limited FDA approval and triggers $175M milestone payment. Commercial distribution planned for fall. 
Via Benzinga
Trump Orders FDA To Fast-Track US Drug Production As Tariff Threat Looms On Imported Medicines: Cites National Security Concerns
President Donald Trump signed an executive order Monday directing the FDA to accelerate approvals for domestic pharmaceutical manufacturing facilities as his administration prepares to announce new... 
Via Benzinga
Topics Government World Trade
Large Cap Biopharmaceutical Update: Mixed Performance As Tariffs Loom
Biopharma stocks rally along with many of our SMID cap trades. The market situation with pharmaceuticals is even more complicated because we started off with legislation (the IRA) trying to curb rising... 
Via Talk Markets
Topics ETFs Stocks / Equities
The Major Sector ETFs Got Their Story
XRT has more work to do. At best, the consumer sector is trying to bottom. At worst, this is a rally into resistance. 
Via Talk Markets
Topics ETFs
Major Sector ETFs Break For Easter
SMH holds steadfast above the 200-WMA even in the face of the tariffs and chip ban to China. 
Via Talk Markets
Topics Cryptocurrencies ETFs World Trade
RFK Jr.'s Massive Federal Health Workforce Cut Could Take 'Decades To Rebuild,' Warn Experts: 'We Cannot Accurately Assess Whether We Are Truly Making America Healthier'
Experts raise alarms about Health Secretary Robert F. Kennedy Jr's decision to layoff tens of thousands of federal workers, disrupting critical health data collection and research efforts. 
Via Benzinga
Topics Workforce
Corvus Pharma Stock Dips On Bigger-Than-Feared Q4 Loss, But Retail’s Faith Grows Stronger
Research and development expenses in the reported quarter rose by $2 million, primarily due to increased spending on the soquelitinib clinical trial for T-cell lymphoma. 
Via Stocktwits
Lexeo Therapeutics Sees Biggest Retail Follower Surge Among Biotech Stocks After Record-Breaking Rally: What's The Big Draw?
The company reported an adjusted Q4 loss of $0.78 per share, beating expectations for a $0.81 loss. 
Via Stocktwits
Can Buying In The Broader Market Pick Up Steam?
Both SPY and QQQ must get back over and close above their 50-WMA to convince bulls the move Friday, while a reversal in the works, is not just a dead cat bounce. 
Via Talk Markets
Topics ETFs
BioNTech's 2025 Revenue View, Vaccine Policy Uncertainty Prompt Price-Target Cut: Retail Stays Cautiously Optimistic
For the current year, BioNTech projected revenue of 1.7 billion euros to 2.2 billion euros, below the market consensus of 2.54 billion euros and a fall from last year's 2.75 billion euros. 
Via Stocktwits
< Previous 1 2 3 4 5 6 7 8 9
...
26 27 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.